Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET
Dyne Therapeutics (Nasdaq: DYN) has announced plans to release new clinical data from its Phase 1/2 ACHIEVE clinical trial on January 10, 2025. The company will host a webcast and investor conference call at 8:00 a.m. ET on the same day, with a press release to be issued before the event. The presentation will be accessible through the Events & Presentations page on Dyne's website, with a replay available for 90 days afterward. An accompanying slide presentation will also be provided for investors.
Dyne Therapeutics (Nasdaq: DYN) ha annunciato piani per rilasciare nuovi dati clinici relativi al suo trial clinico di fase 1/2 ACHIEVE il 10 gennaio 2025. L'azienda ospiterà un webcast e una conferenza telefonica per investitori alle 8:00 a.m. ET lo stesso giorno, con un comunicato stampa che verrà emesso prima dell'evento. La presentazione sarà accessibile attraverso la pagina Eventi e Presentazioni sul sito web di Dyne, con una registrazione disponibile per 90 giorni dopo. Verrà fornita anche una presentazione in diapositiva per gli investitori.
Dyne Therapeutics (Nasdaq: DYN) ha anunciado planes para publicar nuevos datos clínicos de su ensayo clínico de fase 1/2 ACHIEVE el 10 de enero de 2025. La empresa realizará un webcast y una conferencia telefónica para inversores a las 8:00 a.m. ET el mismo día, con un comunicado de prensa que se emitirá antes del evento. La presentación estará disponible a través de la página de Eventos y Presentaciones en el sitio web de Dyne, con una repetición disponible durante 90 días después. También se proporcionará una presentación en diapositivas para los inversores.
Dyne Therapeutics (Nasdaq: DYN)는 2025년 1월 10일에 1/2상 ACHIEVE 임상 시험의 새로운 임상 데이터를 발표할 계획을 발표했습니다. 회사는 같은 날 오전 8시(ET)에 웹캐스트와 투자자 컨퍼런스 콜을 진행하며, 이벤트 이전에 보도 자료가 배포될 예정입니다. 발표는 Dyne 웹사이트의 이벤트 및 프레젠테이션 페이지에서 접근할 수 있으며, 이후 90일 동안 재방송이 제공됩니다. 투자자를 위해 슬라이드 프레젠테이션도 제공될 것입니다.
Dyne Therapeutics (Nasdaq: DYN) a annoncé des plans pour publier de nouvelles données cliniques issues de son essai clinique de phase 1/2 ACHIEVE le 10 janvier 2025. L'entreprise organisera un webcast et une conférence téléphonique pour les investisseurs à 8h00 (ET) ce jour-là, avec un communiqué de presse qui sera diffusé avant l'événement. La présentation sera accessible via la page Événements et Présentations sur le site internet de Dyne, avec un replay disponible pendant 90 jours après. Une présentation en diapositives accompagnante sera également fournie pour les investisseurs.
Dyne Therapeutics (Nasdaq: DYN) hat Pläne angekündigt, am 10. Januar 2025 neue klinische Daten aus seiner Phase 1/2 ACHIEVE-Studie zu veröffentlichen. Das Unternehmen wird am selben Tag um 8:00 Uhr ET ein Webcast und eine Investorenkonferenz abhalten, mit einer Pressemitteilung, die vor der Veranstaltung veröffentlicht wird. Die Präsentation wird über die Seite „Veranstaltungen & Präsentationen“ auf der Webseite von Dyne zugänglich sein, mit einer Wiederholung für 90 Tage danach. Eine begleitende Folienpräsentation wird ebenfalls für Investoren zur Verfügung gestellt.
- None.
- None.
WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it plans to report new clinical data from the Phase 1/2 ACHIEVE clinical trial on January 10, 2025, and to host a webcast at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event.
Investor Conference Call and Webcast
The live webcast will be available on the Events & Presentations page of the Investors & Media section of Dyne’s website, and a replay will be accessible for 90 days following the presentation. An accompanying slide presentation will also be available. To view the live webcast and replay, please visit https://investors.dyne-tx.com/news-and-events/events-and-presentations.
About Dyne Therapeutics
Dyne Therapeutics is focused on discovering and advancing innovative life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE™ platform, Dyne is developing targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system (CNS). Dyne has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.
Contacts:
Investors
Mike Hencke
Kendall Investor Relations
ir@dyne-tx.com
Media
Stacy Nartker
Dyne Therapeutics
snartker@dyne-tx.com
781-317-1938
FAQ
When will Dyne Therapeutics (DYN) release new ACHIEVE trial data?
How can investors access Dyne Therapeutics' (DYN) ACHIEVE trial data presentation?
How long will the replay of DYN's ACHIEVE trial data presentation be available?
What phase is Dyne Therapeutics' ACHIEVE trial currently in?
